- Home
- PSO vs HALO Comparison
PSO vs HALO Comparison
Compare PSO & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSO
- HALO
- Stock Information
- Founded
- PSO 1844
- HALO 1998
- Country
- PSO United Kingdom
- HALO United States
- Employees
- PSO N/A
- HALO N/A
- Industry
- PSO Books
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSO Consumer Discretionary
- HALO Health Care
- Exchange
- PSO Nasdaq
- HALO Nasdaq
- Market Cap
- PSO 8.4B
- HALO 7.6B
- IPO Year
- PSO 2000
- HALO N/A
- Fundamental
- Price
- PSO $13.06
- HALO $73.13
- Analyst Decision
- PSO
- HALO Buy
- Analyst Count
- PSO 0
- HALO 12
- Target Price
- PSO N/A
- HALO $73.33
- AVG Volume (30 Days)
- PSO 769.8K
- HALO 2.6M
- Earning Date
- PSO 01-01-0001
- HALO 11-03-2025
- Dividend Yield
- PSO 2.51%
- HALO N/A
- EPS Growth
- PSO 31.65
- HALO 56.68
- EPS
- PSO 0.90
- HALO 4.74
- Revenue
- PSO $4,822,578,436.00
- HALO $1,242,852,000.00
- Revenue This Year
- PSO $2.17
- HALO $32.47
- Revenue Next Year
- PSO $5.10
- HALO $24.31
- P/E Ratio
- PSO $13.74
- HALO $15.34
- Revenue Growth
- PSO N/A
- HALO 31.19
- 52 Week Low
- PSO $12.85
- HALO $46.26
- 52 Week High
- PSO $17.90
- HALO $79.50
- Technical
- Relative Strength Index (RSI)
- PSO 36.57
- HALO 63.53
- Support Level
- PSO $12.95
- HALO $68.09
- Resistance Level
- PSO $13.17
- HALO $70.81
- Average True Range (ATR)
- PSO 0.15
- HALO 2.26
- MACD
- PSO 0.01
- HALO 0.46
- Stochastic Oscillator
- PSO 38.32
- HALO 80.82
About PSO Pearson Plc
UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.